Deutsche Bank keeps Buy for Medios stock at EUR 16 target

Published on 10/13/2026 at 05:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 8.40 percent to EUR 1.07 billion in the first half of 2026. Deutsche Bank set a EUR 16.00 target for Medios stock.

Key points in brief

Deutsche Bank Research retained a Buy rating and a EUR 16.00 target for Medios on September 30, 2026.
Medios targets EUR 3.1 billion in revenue and EUR 170 million in adjusted EBITDA by 2031.
First-half 2026 revenue rose 8.40 percent to EUR 1.07 billion, while net income declined 32.90 percent year over year.
The Xetra close was EUR 10.32 on October 12, 2026, against a 52-week range of EUR 9.98 to EUR 17.44.

Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und Medikamentenfläschchen auf grauem Grund — Medios AG (DE000A1MMCC8) wird als Flatlay mit Aktienzertifikat, ISIN-Karte und pharmazeutischen Utensilien inszeniert, Illustration mit AI erstellt.

Medios (ISIN DE000A1MMCC8) carries a EUR 16.00 target after FinanzNachrichten reported Deutsche Bank Research retained its Buy rating on September 30, 2026. The target places the analyst reference above the October 12 Xetra close of EUR 10.32, while Medios stock remains near the lower end of its EUR 9.98 to EUR 17.44 52-week range.

Three dates define the strategy

Medios reported first-quarter 2026 revenue growth of 8.90 percent in its Q1 update dated May 12, 2026, according to Quartr. The first-half update dated August 13, 2026 showed revenue of EUR 1,074.9 million, up 8.40 percent year over year, while net income after tax fell 32.90 percent.

On September 29, 2026, Medios presented its Medios Next Level strategy and targeted EUR 3.1 billion in revenue by 2031, up 50.00 percent from EUR 2.1 billion in 2025. The same EQS News release set a target of EUR 170 million for adjusted EBITDA, compared with EUR 87 million under the newly defined 2025 baseline.

What does the target require?

The strategic arithmetic is demanding: revenue is targeted to rise EUR 1.0 billion from the 2025 baseline, while adjusted EBITDA is targeted to increase EUR 83 million. Medios also set a 2.0 times internal net debt to adjusted EBITDA ceiling, compared with 1.32 times reported for the first half of 2026.

The strategy combines Specialty Pharma Supply with Compounding and assigns the higher-margin Compounding business the main earnings role. The company also described annual capital expenditure of EUR 10 million to EUR 15 million and cumulative acquisition capacity of EUR 325 million through 2031 in the September 29 release.

Stock stays close to its yearly low

Medios had a market capitalization of EUR 263.2 million as of October 12, 2026, with 31,101 shares traded in the recorded session. The October 12 Xetra close of EUR 10.32 stood EUR 0.34 above the 52-week low and EUR 7.12 below the high, keeping the valuation context firmly tied to execution of the new plan.

Medios is scheduled to publish its third-quarter 2026 statement on November 10, 2026, according to the reporting calendar included with the EQS release. The next milestone therefore combines a quantified operating update with the first regular test of the strategy after the Capital Markets Day.

Dates and valuation set the next test

The next dated company event is the third-quarter statement on November 10, 2026. For investors, the key comparison is whether revenue growth can remain above the 8.40 percent first-half rate while profitability moves toward the targeted adjusted EBITDA level.

The Xetra close was EUR 10.32 on October 12, 2026. The stock therefore sat EUR 5.68 below the EUR 16.00 Deutsche Bank target cited on September 30, 2026.

Market context: Market report DAX.